Odyssey Therapeutics to Present Phase 2a Study Design at ACG 2026
The company plans to present the design of a Phase 2a study evaluating OD-001 in combination with vedolizumab.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The company plans to present the design of a Phase 2a study evaluating OD-001 in combination with vedolizumab.